BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Goldman Sachs Remains Bullish on BioMarin Pharma (BMRN) Following 1Q
April 26, 2018 8:12 AM EDTGoldman Sachs reiterated a Buy rating and $132.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's 1Q earnings release. BMRN reported total revenue of $373.4mn, above FactSet consensus of $349mn, driven primarily by the adoption of the new revenue recognition principle for... More
